Zacks Investment Research upgraded shares of BIODELIVERY SCI (BDSI) from UNDERPERFORM to NEUTRAL on January 14, 2013, with a target price of $4.90.
BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any process, substance, or combination thereof, that delivers drugs into the body.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on BIODELIVERY SCI (BDSI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment